H.C. Wainwright amps up
Genmab stock price target to $40, citing a solid pipeline. Genmab has been involved in numerous transactions with shares and linked securities. In 2025, Genmab reported a 19% revenue growth to $3.7B driven mainly by the sales of their proprietary medicine. Further, Genmab has started a DKK 725 million share buy-back program. The Genmab stock is expected to spike according to options market predictions. With the 2026 outlook and Abkinley's victory, Genmab's bull case has been reset.
Jefferies Financial Group initialized their coverage on this stock while the CFO's insider share sale was also disclosed. The margin compression in Q4 posed challenges to the bullish growth and valuation narratives. However, EPS missed the Q4 forecast yet the stock rose.
EPKINLY trial results prompted a price cut for the Genmab (GMAB) stock. According to Wall Street, Deutsche Bank sees oncology upside in Genmab's shares. Interestingly, Genmab has shown significant decrease in short interest and expects their 2025 results and capital reduction to be approved at the March 19 AGM.
H.C. Wainwright aligns with Genmab A/S (GMAB) due to robust sales for DARZALEX. Additionally, Genmab enters ranks of stocks with RS Ratings higher than 90. Lastly, there are talks of Genmab acquiring Merus for $8bn.
Genmab Stocks News Analytics from Mon, 02 Jun 2025 07:00:00 GMT to Fri, 20 Feb 2026 15:32:13 GMT -
Rating 8
- Innovation 2
- Rumor -6
